Cargando…

Reducing bias in open-label trials where blinded outcome assessment is not feasible: strategies from two randomised trials

BACKGROUND: Blinded outcome assessment is recommended in open-label trials to reduce bias, however it is not always feasible. It is therefore important to find other means of reducing bias in these scenarios. METHODS: We describe two randomised trials where blinded outcome assessment was not possibl...

Descripción completa

Detalles Bibliográficos
Autores principales: Kahan, Brennan C, Cro, Suzie, Doré, Caroline J, Bratton, Daniel J, Rehal, Sunita, Maskell, Nick A, Rahman, Najib, Jairath, Vipul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4247637/
https://www.ncbi.nlm.nih.gov/pubmed/25416527
http://dx.doi.org/10.1186/1745-6215-15-456
_version_ 1782346671026339840
author Kahan, Brennan C
Cro, Suzie
Doré, Caroline J
Bratton, Daniel J
Rehal, Sunita
Maskell, Nick A
Rahman, Najib
Jairath, Vipul
author_facet Kahan, Brennan C
Cro, Suzie
Doré, Caroline J
Bratton, Daniel J
Rehal, Sunita
Maskell, Nick A
Rahman, Najib
Jairath, Vipul
author_sort Kahan, Brennan C
collection PubMed
description BACKGROUND: Blinded outcome assessment is recommended in open-label trials to reduce bias, however it is not always feasible. It is therefore important to find other means of reducing bias in these scenarios. METHODS: We describe two randomised trials where blinded outcome assessment was not possible, and discuss the strategies used to reduce the possibility of bias. RESULTS: TRIGGER was an open-label cluster randomised trial whose primary outcome was further bleeding. Because of the cluster randomisation, all researchers in a hospital were aware of treatment allocation and so could not perform a blinded assessment. A blinded adjudication committee was also not feasible as it was impossible to compile relevant information to send to the committee in a blinded manner. Therefore, the definition of further bleeding was modified to exclude subjective aspects (such as whether symptoms like vomiting blood were severe enough to indicate the outcome had been met), leaving only objective aspects (the presence versus absence of active bleeding in the upper gastrointestinal tract confirmed by an internal examination). TAPPS was an open-label trial whose primary outcome was whether the patient was referred for a pleural drainage procedure. Allowing a blinded assessor to decide whether to refer the patient for a procedure was not feasible as many clinicians may be reluctant to enrol patients into the trial if they cannot be involved in their care during follow-up. Assessment by an adjudication committee was not possible, as the outcome either occurred or did not. Therefore, the decision pathway for procedure referral was modified. If a chest x-ray indicated that more than a third of the pleural space filled with fluid, the patient could be referred for a procedure; otherwise, the unblinded clinician was required to reach a consensus on referral with a blinded assessor. This process allowed the unblinded clinician to be involved in the patient’s care, while reducing the potential for bias. CONCLUSIONS: When blinded outcome assessment is not possible, it may be useful to modify the outcome definition or method of assessment to reduce the risk of bias. TRIAL REGISTRATION: TRIGGER: ISRCTN85757829. Registered 26 July 2012. TAPPS: ISRCTN47845793. Registered 28 May 2012.
format Online
Article
Text
id pubmed-4247637
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-42476372014-11-30 Reducing bias in open-label trials where blinded outcome assessment is not feasible: strategies from two randomised trials Kahan, Brennan C Cro, Suzie Doré, Caroline J Bratton, Daniel J Rehal, Sunita Maskell, Nick A Rahman, Najib Jairath, Vipul Trials Research BACKGROUND: Blinded outcome assessment is recommended in open-label trials to reduce bias, however it is not always feasible. It is therefore important to find other means of reducing bias in these scenarios. METHODS: We describe two randomised trials where blinded outcome assessment was not possible, and discuss the strategies used to reduce the possibility of bias. RESULTS: TRIGGER was an open-label cluster randomised trial whose primary outcome was further bleeding. Because of the cluster randomisation, all researchers in a hospital were aware of treatment allocation and so could not perform a blinded assessment. A blinded adjudication committee was also not feasible as it was impossible to compile relevant information to send to the committee in a blinded manner. Therefore, the definition of further bleeding was modified to exclude subjective aspects (such as whether symptoms like vomiting blood were severe enough to indicate the outcome had been met), leaving only objective aspects (the presence versus absence of active bleeding in the upper gastrointestinal tract confirmed by an internal examination). TAPPS was an open-label trial whose primary outcome was whether the patient was referred for a pleural drainage procedure. Allowing a blinded assessor to decide whether to refer the patient for a procedure was not feasible as many clinicians may be reluctant to enrol patients into the trial if they cannot be involved in their care during follow-up. Assessment by an adjudication committee was not possible, as the outcome either occurred or did not. Therefore, the decision pathway for procedure referral was modified. If a chest x-ray indicated that more than a third of the pleural space filled with fluid, the patient could be referred for a procedure; otherwise, the unblinded clinician was required to reach a consensus on referral with a blinded assessor. This process allowed the unblinded clinician to be involved in the patient’s care, while reducing the potential for bias. CONCLUSIONS: When blinded outcome assessment is not possible, it may be useful to modify the outcome definition or method of assessment to reduce the risk of bias. TRIAL REGISTRATION: TRIGGER: ISRCTN85757829. Registered 26 July 2012. TAPPS: ISRCTN47845793. Registered 28 May 2012. BioMed Central 2014-11-21 /pmc/articles/PMC4247637/ /pubmed/25416527 http://dx.doi.org/10.1186/1745-6215-15-456 Text en © Kahan et al.; licensee BioMed Central Ltd. 2014 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Kahan, Brennan C
Cro, Suzie
Doré, Caroline J
Bratton, Daniel J
Rehal, Sunita
Maskell, Nick A
Rahman, Najib
Jairath, Vipul
Reducing bias in open-label trials where blinded outcome assessment is not feasible: strategies from two randomised trials
title Reducing bias in open-label trials where blinded outcome assessment is not feasible: strategies from two randomised trials
title_full Reducing bias in open-label trials where blinded outcome assessment is not feasible: strategies from two randomised trials
title_fullStr Reducing bias in open-label trials where blinded outcome assessment is not feasible: strategies from two randomised trials
title_full_unstemmed Reducing bias in open-label trials where blinded outcome assessment is not feasible: strategies from two randomised trials
title_short Reducing bias in open-label trials where blinded outcome assessment is not feasible: strategies from two randomised trials
title_sort reducing bias in open-label trials where blinded outcome assessment is not feasible: strategies from two randomised trials
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4247637/
https://www.ncbi.nlm.nih.gov/pubmed/25416527
http://dx.doi.org/10.1186/1745-6215-15-456
work_keys_str_mv AT kahanbrennanc reducingbiasinopenlabeltrialswhereblindedoutcomeassessmentisnotfeasiblestrategiesfromtworandomisedtrials
AT crosuzie reducingbiasinopenlabeltrialswhereblindedoutcomeassessmentisnotfeasiblestrategiesfromtworandomisedtrials
AT dorecarolinej reducingbiasinopenlabeltrialswhereblindedoutcomeassessmentisnotfeasiblestrategiesfromtworandomisedtrials
AT brattondanielj reducingbiasinopenlabeltrialswhereblindedoutcomeassessmentisnotfeasiblestrategiesfromtworandomisedtrials
AT rehalsunita reducingbiasinopenlabeltrialswhereblindedoutcomeassessmentisnotfeasiblestrategiesfromtworandomisedtrials
AT maskellnicka reducingbiasinopenlabeltrialswhereblindedoutcomeassessmentisnotfeasiblestrategiesfromtworandomisedtrials
AT rahmannajib reducingbiasinopenlabeltrialswhereblindedoutcomeassessmentisnotfeasiblestrategiesfromtworandomisedtrials
AT jairathvipul reducingbiasinopenlabeltrialswhereblindedoutcomeassessmentisnotfeasiblestrategiesfromtworandomisedtrials